GSK Tries To Halt Teva's Generic Combivir Launch

By Ryan Davis

Law360, New York (March 10, 2010, 11:53 AM ET) -- GlaxoSmithKline PLC has asked a court to block Teva Pharmaceuticals USA Inc.'s planned May launch of a generic version of GSK's HIV drug Combivir.

GSK filed a motion for a preliminary injunction Friday in the U.S. District Court for the District of Delaware.

The company sued Teva in 2007, alleging that the proposed generic product would infringe a single GSK patent for Combivir, U.S. Patent Number 5,859,021, which is scheduled to expire in 2016.

The motion asks for an injunction barring Teva from making or selling...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles